This study is testing a drug called olutasidenib to see if it can help people with certain blood disorders: Clonal Cytopenia of Undetermined Significance (CCUS), Myelodysplastic Syndromes (MDS), and Chronic Myelomonocytic Leukemia (CMML). You may be able to join if you have one of these conditions and your disease has a specific genetic change called an IDH1 mutation. Researchers want to find out how well olutasidenib works to control these conditions and if it is safe. Success would mean seeing a good response to the treatment, like needing fewer blood transfusions. This study plans to enroll 15 participants, but the current recruitment status is unclear.

Study design

This is an interventional study, meaning participants will receive a specific treatment. It is a single-arm study, with 15 planned participants.

What's involved

You would take olutasidenib by mouth twice daily in 28-day cycles. You will also have blood samples and bone marrow procedures. Patients with CCUS receive treatment for up to 18 months, while those with MDS/CMML continue until the disease worsens or side effects are too much.

Compensation

Not stated in the trial record.

Follow-up

After treatment, participants will be followed up every 3 months for up to 3 years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.